Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study.
暂无分享,去创建一个
Yi Yang | William B. Lobb | B. Banahan | Noel E. Wilkin | Yi Yang | V. Thumula | Patrick F Pace | Vennela Thumula | Benjamin F Banahan | Noel E Wilkin | William B Lobb | Patrick F. Pace
[1] H. Rodbard,et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[2] Timothy W. Smith,et al. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[3] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[4] J. Steiner,et al. A Systematic Review of the Literature , 2019, HIV/AIDS and Adolescents.
[5] M. Joffres,et al. Medication Persistence Rates and Factors Associated with Persistence in Patients Following Stroke: A Cohort Study , 2008, BMC neurology.
[6] L Keoki Williams,et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. , 2004, Diabetes care.
[7] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[8] A. Rodday,et al. Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors. , 2007, Health affairs.
[9] Richard H. Chapman,et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. , 2005 .
[10] B. Hoogwerf,et al. Managing type 2 diabetes: going beyond glycemic control. , 2015, Journal of managed care pharmacy : JMCP.
[11] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[12] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[13] J. Tjia,et al. Will the Medicare Prescription Drug Benefit Eliminate Cost Barriers for Older Adults with Diabetes Mellitus? , 2006, Journal of the American Geriatrics Society.
[14] R. Deyo,et al. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.
[15] A V Prochazka,et al. The assessment of refill compliance using pharmacy records: methods, validity, and applications. , 1997, Journal of clinical epidemiology.
[16] F. Camacho,et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. , 2003, Clinical therapeutics.
[17] David B Lawrence,et al. Relationship of Oral Antihyperglycemic (Sulfonylurea or Metformin) Medication Adherence and Hemoglobin A1c Goal Attainment for HMO Patients Enrolled in a Diabetes Disease Management Program , 2006, Journal of managed care pharmacy : JMCP.
[18] Denys T. Lau,et al. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. , 2004, Diabetes care.
[19] J. Cramer. A Systematic Review of Adherence With Medications for Diabetes , 2004 .
[20] D. Meltzer,et al. The Effect of the Medicare Part D Prescription Benefit on Drug Utilization and Expenditures , 2008, Annals of Internal Medicine.
[21] Michael M. Engelgau,et al. Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population , 2006, Diabetes Care.
[22] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[23] John S Yudkin,et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.
[24] J. Cramer. A systematic review of adherence with medications for diabetes. , 2004, Diabetes care.
[25] Jennifer Y. Liu,et al. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes , 2004, Journal of General Internal Medicine.
[26] J. Dora,et al. Standards of Medical Care in Diabetes—2008 , 2008, Diabetes Care.
[27] N. Clark,et al. Standards of Medical Care in Diabetes: Response to Power , 2006 .
[28] Lawrence O Gostin,et al. Health information privacy. , 1995, Cornell law review.
[29] R. Rubin,et al. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. , 2005, The American journal of medicine.
[30] P Michael Ho,et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. , 2008, American heart journal.
[31] Peter J. Neumann,et al. Long-term persistence in use of statin therapy in elderly patients. , 2002, JAMA.
[32] Michael L. Johnson,et al. Patterns of antihypertensive therapy among patients with diabetes , 2005, Journal of General Internal Medicine.
[33] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[34] R. Verbrugge,et al. Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost , 2005, Medical care.
[35] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[36] K. Bennett,et al. A review of studies of adherence with antihypertensive drugs using prescription databases , 2005, Therapeutics and clinical risk management.
[37] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[38] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[39] C. Cooke,et al. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization. , 2015, Journal of managed care pharmacy : JMCP.
[40] D. Grobbee,et al. Cardiovascular drug use and hospitalizations attributable to type 2 diabetes. , 2001, Diabetes care.
[41] V. Basevi. Standards of medical care in diabetes--2007. , 2009, Diabetes care.
[42] Femida Gwadry-Sridhar,et al. A checklist for medication compliance and persistence studies using retrospective databases. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[43] D. S. Gochman,et al. Handbook of health behavior research , 1997 .
[44] I. Lerman. Adherence to treatment: the key for avoiding long-term complications of diabetes. , 2005, Archives of medical research.
[45] Won Chan Lee,et al. Drug Persistency Patterns for Patients Treated With Rivastigmine or Donepezil in Usual Care Settings , 2005, Journal of managed care pharmacy : JMCP.
[46] Yelena Rozenfeld,et al. Oral antidiabetic medication adherence and glycemic control in managed care. , 2008, The American journal of managed care.
[47] A. Unger,et al. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. , 2005, Clinical therapeutics.
[48] K. Secnik,et al. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. , 2007, Clinical therapeutics.